Key facts
- Gesynta Pharma’s last known valuation is $42.8M (Dec 2021).
- It has raised $77.8M; the latest was Later Stage VC ($36.8M) in Oct 2025.
- Notable investors include Innovestor, Industrifonden, Nordic Mentor Network For Entrepreneurship, Amboy Street Ventures, Stephen Industries — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Gesynta Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Gesynta Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gesynta Pharma
Developer of a clinical-stage pharmaceutical portfolio designed to treat inflammatory diseases by inhibiting pro-inflammatory pathways. The company offers selective enzyme-targeting drug candidates with favorable safety and pharmacological profiles, enabling patients with inflammatory conditions such as endometriosis to experience non-hormonal symptom relief and improved quality of life.
- Sector
- Healthcare
- HQ
- Stockholm, Sweden
- Founded
- 2017
- Employees
- 11
- Website
- gesynta.se/
- Ownership
- Privately Held (backing)
Gesynta Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gesynta Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gesynta Pharma in its N-PORT filings yet. We sweep new filings monthly.